Warfarin Therapy: Survey of Patients' Knowledge of their Drug Regimen.

BACKGROUND Warfarin is utilised for the treatment of thromboembolic disease. Its use demands a careful and continual monitoring given its narrow therapeutic index and potentially life-threatening complications. The aim of this study was to assess the extent of patients' knowledge of their warfarin therapy. METHODS A total of 200 consecutive patients from a single community hospital completed an online survey questionnaire (www.eSurveysPro.com). Using the responses to the questionnaire, we recorded compliance to warfarin therapy, knowledge about drug interactions, adverse effects of warfarin therapy, complications, and resulting hospitalisation. RESULTS We recruited 200 patients, 55% (109/200) women and 45% (91/200) men, among which 88% were compliant with their daily medication. Of the 200 patients, 56% were unaware of any potential drug interactions, 58% were unaware of any adverse effects, 27% had experienced adverse effects, 12% had been hospitalised because of adverse effects (33% of which were due to bleeding), and 65% kept a personal record of their international normalised ratio. CONCLUSION Despite the high level of compliance, patient knowledge of warfarin therapy was low. Given the potential drug interactions and complexities involved with warfarin therapy, it is of high importance that medical professionals educate their patients and make them aware of any impending signs of emergent medical complications.

[1]  G. Ginsburg,et al.  Clinical application of cardiovascular pharmacogenetics. , 2012, Journal of the American College of Cardiology.

[2]  A. Smaldone,et al.  The use of vitamin K supplementation to achieve INR stability: A systematic review and meta‐analysis , 2013, Journal of the American Association of Nurse Practitioners.

[3]  C. Gordon,et al.  Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS). , 2014, Rheumatology.

[4]  A. Spyropoulos,et al.  A new paradigm shift in antithrombotic therapy , 2013, Front. Pharmacol..

[5]  D. Bates,et al.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting. , 2003, JAMA.

[6]  W. Aronow,et al.  Update on Pharmacologic Therapy for Pulmonary Embolism , 2014, Journal of cardiovascular pharmacology and therapeutics.

[7]  Robert Gross,et al.  The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. , 2007, Archives of internal medicine.

[8]  D. Roberts,et al.  Case report: Cranberry juice and warfarin. , 2011, Home healthcare nurse.

[9]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. , 2008, The Journal of pediatrics.

[10]  N. Srinivas.  Cranberry juice ingestion and clinical drug-drug interaction potentials; review of case studies and perspectives. , 2013, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[11]  O. Hanon,et al.  Use of Vitamin K Antagonist Therapy in Geriatrics: A French National Survey from the French Society of Geriatrics and Gerontology (SFGG) , 2013, Drugs & Aging.

[12]  U. Abildgaard,et al.  Gains and losses of warfarin therapy as performed in an anticoagulation clinic , 2006, Journal of internal medicine.

[13]  S. Yusuf,et al.  Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial , 2010, The Lancet Neurology.

[14]  C. Ulbricht,et al.  Clinical evidence of herb-drug interactions: a systematic review by the natural standard research collaboration. , 2008, Current drug metabolism.

[15]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[16]  Stacy L. Haber,et al.  Cranberry and warfarin interaction: a case report and review of the literature. , 2012, The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists.

[17]  G. Hamann,et al.  Warfarin-Cranberry Juice Interaction , 2011, The Annals of pharmacotherapy.

[18]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.

[19]  N. Shapiro,et al.  Interaction Between Warfarin and Cranberry Juice , 2006, Pharmacotherapy.

[20]  R. Wong,et al.  Relationship Between Patients’ Warfarin Knowledge and Anticoagulation Control , 2003, The Annals of pharmacotherapy.

[21]  C. Chow,et al.  Factors Influencing Patient Knowledge of Warfarin Therapy After Mechanical Heart Valve Replacement , 2006, The Journal of cardiovascular nursing.

[22]  M. Hennerici,et al.  Antithrombotic therapy in transient ischemic attack patients. , 2014, Frontiers of neurology and neuroscience.